Pediatric Antiphospholipid Syndrome

  • Cassyanne L. Aguiar
  • Arzu Soybilgic
  • Tadej Avcin
  • Barry L. Myones
Antiphospholipid Syndrome (D Erkan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Antiphospholipid Syndrome


Antiphospholipid syndrome (APS) is a multisystem autoimmune condition characterized by vascular thromboses associated with persistently positive antiphospholipid antibodies. There is currently a paucity of data (incidence, prevalence, thrombosis risk, and effective treatment) in pediatric APS. The purpose of this report is to review the current literature on APS in children and neonates, identify the gaps in current knowledge, and suggest avenues for studies to fill those gaps.


Antiphospholipid syndrome Antiphospholipid antibodies Pediatric Neonatal Catastrophic antiphospholipid syndrome Treatment Thrombotic risk 



The authors would like to acknowledge the suggestions and recommendations of Patricia Massicotte, M.D. of the University of Alberta.

Compliance with Ethics Guidelines

Conflict of Interest

Cassyanne L. Aguiar, Arzu Soybilgic, Tadej Avcin, and Barry L. Myones declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMedGoogle Scholar
  2. 2.
    Avcin T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford). 2001;40(5):565–73.Google Scholar
  3. 3.
    Berkun Y, Simchen M, Strauss T, et al. Antiphospholipid antibodies in neonates with stroke–a unique entity or variant of antiphospholipid syndrome? Lupus. 2014;23(10):986–93.PubMedGoogle Scholar
  4. 4.
    Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007;9(3):212–8.PubMedGoogle Scholar
  5. 5.
    Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002;46(2):545–52.PubMedGoogle Scholar
  6. 6.
    Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus. 1998;7 Suppl 2:S52–4.PubMedGoogle Scholar
  7. 7.
    Gharavi AE, Vega-Ostertag M, Espinola RG, et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus. 2004;13(1):17–23.PubMedGoogle Scholar
  8. 8.
    Wenzel C, Stoiser B, Locker G, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30(4):763–70.PubMedGoogle Scholar
  9. 9.
    Cruz-Tapias P, Blank M, Anaya JM, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMedGoogle Scholar
  10. 10.
    Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21(7):711–4.PubMedGoogle Scholar
  11. 11.
    Andreoli L, Nalli C, Motta M, et al. Anti-B2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Ann Rheum Dis. 2011;70(2):380–3.PubMedGoogle Scholar
  12. 12.
    Wahezi DM, Ilowite NT, Wu XX, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013;22(7):702–11.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Guerin J, Casey E, Feighery C, et al. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31(2):109–16.PubMedGoogle Scholar
  14. 14.
    Kumar S, Papalardo E, Sunkureddi P, et al. Isolated elevation of IgA anti-Beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18(11):1011–4.PubMedGoogle Scholar
  15. 15.
    Samarkos M, Davies K, Gordon C, et al. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol. 2006;25(2):199–204.PubMedGoogle Scholar
  16. 16.
    Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.PubMedGoogle Scholar
  17. 17.
    Erkan D, Lockshin M. High risk antiphospholipid antibody profile: matter of the number or titer of tests? E-letter to the editor (re: Incidence of first thrombembolic event in asymptomatic carries of high-risk aPL profile: a multicenter prospective study, Pengo et al. Blood 2011;17:4714). Published online on 24 January 2012, available at:
  18. 18.
    Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32.PubMedGoogle Scholar
  19. 19.
    Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5(5):925–30.PubMedGoogle Scholar
  20. 20.
    Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85–94.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatol Med. 2006;11(3):198–206.Google Scholar
  22. 22.
    Male C, Lechner K, Eichinger S, et al. Clinical significance of lupus anticoagulants in children. J Pediatr. 1999;134(2):199–205.PubMedGoogle Scholar
  23. 23.
    Flanders MM, Crist RA, Roberts WL, et al. Pediatric reference intervals for seven common coagulation assays. Clin Chem. 2005;51(9):1738–42.PubMedGoogle Scholar
  24. 24.••
    Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–7. Most comprehensive descriptive characteristics of pediatric APS from an international registry. PubMedGoogle Scholar
  25. 25.
    Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci. 2005;1051:465–86.PubMedGoogle Scholar
  26. 26.
    Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74(1):415–25.PubMedGoogle Scholar
  27. 27.
    Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251–7.PubMedGoogle Scholar
  28. 28.
    Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein 1 antibodies in infants born to mother with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol. 2006;23(4):247–51.PubMedGoogle Scholar
  29. 29.
    Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol. 1994;1(6):667–9.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Samarkos M, Davies KA, Gordon C, et al. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford). 2001;40(9):1026–32.Google Scholar
  32. 32.
    Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclases. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997;40(11):1998–2006.PubMedGoogle Scholar
  33. 33.
    Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus. 2007;16(8):634–41.Google Scholar
  34. 34.
    Peixoto MV, de Carvalho JF, Rodrigues CE. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res. 2014;2014:672603.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Boffa MC, Aurousseau MH, Lachassinne E, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus. 2004;13(9):713–7.PubMedGoogle Scholar
  36. 36.
    Boffa MC, Lachassinne E, Boinot C, et al. European registry of babies born to mothers with antiphospholipid syndrome: a result update. Lupus. 2009;18(10):900–4.PubMedGoogle Scholar
  37. 37.
    Mekinian A, Carbillon L, Nicaise-Roland P, et al. Mothers’ antiphospholipid antibodies during pregnancy and the relation to offspring outcome. Clin Exp Rheumatol. 2014;32(3):446.PubMedGoogle Scholar
  38. 38.•
    Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis. 2013;72(2):217–22. A prospective study aiming to describe the long-term outcomes of children born to mothers with antiphospholipid syndrome. PubMedCentralPubMedGoogle Scholar
  39. 39.
    Nalli C, Iodice A, Andreoli L, et al. The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus. 2014;23(6):507–17.PubMedGoogle Scholar
  40. 40.
    Ross G, Sammaritano L, Nass R, et al. Affects of mother’s autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003;157(4):397–402.PubMedGoogle Scholar
  41. 41.
    Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med. 1999;27(3):183–7.PubMedGoogle Scholar
  42. 42.
    Nacinovich R, Galli J, Bomba M, et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum. 2008;59(3):345–51.PubMedGoogle Scholar
  43. 43.
    Abisror N, Mekinian A, Lachassinne E, et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum. 2013;43(3):348–51.PubMedGoogle Scholar
  44. 44.•
    Gordon O, Almagor Y, Fridler D, et al. De novo neonatal antiphospholipid syndrome: a case report and review of the literature. Semin Arthritis Rheum. 2014;44(2):241–5. A recent review of de novo neonatal APS. PubMedGoogle Scholar
  45. 45.
    Hansen K, Kong D, Moore K, et al. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001;28(9):2018–24.PubMedGoogle Scholar
  46. 46.
    Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothromboitc risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003;30(11):2385–91.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Rosendaal F, Siscovick D, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89(8):2817–21.PubMedGoogle Scholar
  48. 48.
    Giron-Gonzalez J, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560–7.Google Scholar
  49. 49.
    Kaul M, Erkan D, Sammaritano L, et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927–30.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Tolbert J, Carpenter SL. Common acquired causes of thrombosis in children. Curr Probl Pediatr Adolesc Health Care. 2013;43(7):169–77.PubMedGoogle Scholar
  51. 51.
    Avcin T, Cimaz R, Rozman B, Ped-APS Registry Collaborative Group. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus. 2009;18(10):894–9.PubMedGoogle Scholar
  52. 52.
    Albisetti M, Moeller A, Waldvogel K, et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol. 2007;117(3):149–55.PubMedGoogle Scholar
  53. 53.
    Revel-Vilk S, Chan A, Bauman M, et al. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost. 2003;1(5):915–21.PubMedGoogle Scholar
  54. 54.
    Yang JY, Chan AK. Pediatric thrombophilia. Pediatr Clin North Am. 2013;60(6):1443–62.PubMedGoogle Scholar
  55. 55.•
    Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011;37(7):802–9. A meta-analysis describing the impact of antiphospholipid antibodies on the risk of thrombotic events in children. Google Scholar
  56. 56.
    Manco-Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol. 1995;48(4):240–3.PubMedGoogle Scholar
  57. 57.
    Tavil B, Ozyurek E, Gumruk F, et al. Antiphospholipid antibodies in Turkish children with thrombosis. Blood Coagul Fibrinolysis. 2007;18(4):347–52.PubMedGoogle Scholar
  58. 58.
    Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19(4):406–11.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Lampropoulos CE, Koutroumanidis M, Reynolds PP, et al. Electroencephalography in the assessment of neuropsychiatric manifestation in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005;52(3):841–6.PubMedGoogle Scholar
  60. 60.
    Biernacka-Zielinska M, Lipinska J, Szymanska-Kaluza J, et al. Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report. J Med Case Rep. 2013;7:221.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23:1449–51.PubMedGoogle Scholar
  62. 62.
    Avcin T, Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008;59(2):206–13.PubMedGoogle Scholar
  63. 63.
    Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33(9):1873–7.PubMedGoogle Scholar
  64. 64.
    von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2002;47(4):414–20.Google Scholar
  65. 65.
    Cimaz R, Romeo A, Scarano A, et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia. 2002;43(1):52–9.PubMedGoogle Scholar
  66. 66.
    Constantin T, Kálovics T, Ponyi A, et al. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Med Sci Monit. 2009;15(4):CR164–9.PubMedGoogle Scholar
  67. 67.
    Avčin T, Markelj G, Nikšič V, et al. Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine. Cephalalgia. 2004;24(10):831–7.Google Scholar
  68. 68.
    Lampropoulos CE, Hughes GR. The antiphospholipid (Hughes’) syndrome: changing the face of neurology. Eur J Intern Med. 2004;15(3):147–50.PubMedGoogle Scholar
  69. 69.
    Careaga M, Hansen RL, Hertz-Piccotto I, et al. Increased anti-phospholipid antibodies in autism spectrum disorders. Mediators Inflamm. 2013;2013:935608.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Zamora-Ustaran A, Escarcega-Alarcón RO, Garcia-Carrasco M, et al. Antiphospholipid syndrome in Mexican children. Isr Med Assoc J. 2012;14(5):286–9.PubMedGoogle Scholar
  71. 71.
    Mazodier K, Arnaud L, Mathian A, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5):251–60.Google Scholar
  72. 72.
    Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850–5.Google Scholar
  73. 73.
    Garcia-Carrasco M, Galarza C, Gómez-Ponce M, et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus. 2007;16(5):366–73.PubMedGoogle Scholar
  74. 74.
    Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.PubMedGoogle Scholar
  75. 75.
    Gattorno M, Falcini F, Ravelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus. 2003;12(6):449–53.PubMedGoogle Scholar
  76. 76.
    Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.Google Scholar
  77. 77.
    Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16(8):627–33.PubMedGoogle Scholar
  78. 78.
    Andrews A, Hickling P. Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Lupus. 1997;6(6):556–7.PubMedGoogle Scholar
  79. 79.
    Caporali R, Ravelli A, Ramenghi B, et al. Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. Arch Dis Child. 1992;67(11):1384–5.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Abend NS, Licht DJ, Spencer CH. Lupus anticoagulant and thrombosis following Henoch-Schonlein purpura. Pediatr Neurol. 2007;36(5):345–7.PubMedGoogle Scholar
  81. 81.
    Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated henoch-Schonlein purpura. Arch Dis Child. 2002;86(2):132–3.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Meglic A, Grosek S, Benedik-Dolnicar M, et al. Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome. Lupus. 2008;17(9):842–5.Google Scholar
  83. 83.
    Sherer Y, Livneh A, Levy Y, et al. Dermatomyositis and polymyositis associated with the antiphospholipid syndrome: a novel overlap syndrome. Lupus. 2000;9(1):42–6.Google Scholar
  84. 84.
    Fung VS, Yiannikas C, Sue CM, et al. Is Sydenham’s chorea an antiphospholipid syndrome? J Clin Neurosci. 1998;5(1):115–8.PubMedGoogle Scholar
  85. 85.
    Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as a presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics. 1999;30(2):96–8.PubMedGoogle Scholar
  86. 86.
    Caporali R, Ravelli A, De Gennaro F, et al. Prevalence of anticardiolipin antibodies in juvenile arthritis. Ann Rheum Dis. 1991;50(9):599–601.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Southwood TR, Roberts-Thomson PJ, Ahern MJ, et al. Autoantibodies in patients with juvenile chronic arthritis and their immediate family relatives. Ann Rheum Dis. 1990;49(12):968–72.PubMedCentralGoogle Scholar
  88. 88.
    Gedalia A, Molina IF, Garcia CO, et al. Anticardiolipin antibodies in childhood rheumatic disorders. Lupus. 1998;7(8):551–3.PubMedGoogle Scholar
  89. 89.
    Rožiĝ M, Trampuš-Bakija A, Rener-Primec Z, et al. Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies. Arthritis Rheum. 2008;58:S711–2.Google Scholar
  90. 90.
    Avcin T, Cimaz R, Meroni PL. Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in paediatric population? Lupus. 2001;10(12):897–8.PubMedGoogle Scholar
  91. 91.
    Cabiedes J, Trejo-Hernandez J, Loredo-Abdala A, et al. Anti-cardiolipin, anticardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population. Arch Med Res. 2002;33(2):175–9.PubMedGoogle Scholar
  92. 92.
    Vaarala O, Palosuo T, Kleemola M, et al. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41(1):8–15.PubMedGoogle Scholar
  93. 93.
    Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology. 2005;210(10):799–805.PubMedGoogle Scholar
  94. 94.
    Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. 2005;142(2):377–80.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Toplak N, Kveder T, Trampuš-Bakija A, et al. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev. 2008;8(2):134–8.PubMedGoogle Scholar
  96. 96.
    Rapizzi E, Ruffatti A, Tonello M, et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal. 2000;14(3):87–90.PubMedGoogle Scholar
  97. 97.
    Siemens HJ, Gutsche S, Brückner S, et al. Antiphospholipid antibodies in children without and in adults with and without thrombophilia. Thromb Res. 2000;98(4):241–7.PubMedGoogle Scholar
  98. 98.
    Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus. 2002;11(1):4–10.PubMedGoogle Scholar
  99. 99.
    Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):553–73.PubMedGoogle Scholar
  100. 100.
    Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am. 2007;33(3):499–523.PubMedGoogle Scholar
  101. 101.
    Becton DL, Stine KC. Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome. J Pediatr. 1997;130(6):998–1000.PubMedGoogle Scholar
  102. 102.
    Lee MT, Nardi MA, Hadzi-Nesic J, et al. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1½-year-old girl: report of a case and review of the literature. Am J Hematol. 1996;51(4):307–14.PubMedGoogle Scholar
  103. 103.
    Yacobovich JR, Uziel Y, Friedman Z, et al. Diffuse muscular haemorrhage as presenting sign of juvenile systemic lupus erythematosus and lupus anticoagulant hypoprothrombinaemia syndrome. Rheumatology (Oxford). 2001;40(5):585–7.Google Scholar
  104. 104.
    Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–8.PubMedGoogle Scholar
  105. 105.
    Orsino A, Schneider R, DeVeber G, et al. Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. J Pediatr Hematol Oncol. 2004;26(5):327–30.PubMedGoogle Scholar
  106. 106.
    Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35(5):322–32.PubMedGoogle Scholar
  107. 107.
    Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008;34(3):282–5.Google Scholar
  108. 108.
    Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–4.PubMedGoogle Scholar
  109. 109.
    Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64(8):1205–9.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Manco-Johnson M, Wang M, Goldenberg N, et al. Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. J Pediatr. 2012;161(4):682–8.Google Scholar
  111. 111.
    Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10(2):74–9.PubMedGoogle Scholar
  112. 112.•
    Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnosis a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013;5(6):305–14. A review article summarizing the diagnostic challenges and recently updated diagnostic algorithms for CAPS. PubMedCentralPubMedGoogle Scholar
  113. 113.•
    Berman H, Rodríguez-Pintó I, Cervera R, et al. Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev. 2014;13(2):157–62. A descriptive analysis of pediatric patients from the CAPS registry. PubMedGoogle Scholar
  114. 114.
    Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12(7):499–503.PubMedGoogle Scholar
  115. 115.
    Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18.PubMedGoogle Scholar
  116. 116.
    Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis Rheum. 2007;56(7):2382–91.PubMedGoogle Scholar
  117. 117.
    Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus. 1997;6(5):467–73.PubMedGoogle Scholar
  118. 118.
    Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192–200.PubMedGoogle Scholar
  119. 119.
    Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8.PubMedGoogle Scholar
  120. 120.
    Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509.PubMedGoogle Scholar
  121. 121.
    Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6(2):98–103.PubMedGoogle Scholar
  122. 122.
    Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):70–6.PubMedGoogle Scholar
  123. 123.
    Nageswara Rao AA, Arteaga GM, Reed AM, et al. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer. 2009;52(4):536–8.PubMedGoogle Scholar
  124. 124.
    Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, et al. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics. 2010;125(6):e1523–8.PubMedGoogle Scholar
  125. 125.•
    Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12(11):1085–90. A descriptive analysis of the use of rituximab in pediatric CAPS. PubMedGoogle Scholar
  126. 126.••
    Erkan D, Aguiar CL, Andrade D, et al. 14th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. A comprehensive review of the various treatments being used and studied for APS. PubMedGoogle Scholar
  127. 127.
    Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185–90.PubMedGoogle Scholar
  128. 128.
    Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.PubMedGoogle Scholar
  129. 129.••
    Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–84. This is a prospective cohort study within the Warfarin versus Aspirin Recurrent Stroke Study (WARSS) [126] that specified in advance APS-related data and sample collection parameters and could be a model for future studies. PubMedGoogle Scholar
  130. 130.
    Liu X-W, Pierangeli SS, Barker J, et al. RBC adhesion to cremaster endothelium in mice with abnormal hemoglobin is increased by topical endotoxin. Ann N Y Acad Sci. 1998;850:391–3.PubMedGoogle Scholar
  131. 131.
    Westerman M, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 1999;134(4):352–62.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Cassyanne L. Aguiar
    • 1
  • Arzu Soybilgic
    • 2
  • Tadej Avcin
    • 3
    • 4
  • Barry L. Myones
    • 5
  1. 1.Pediatric RheumatologyCohen Children’s Medical Center—North Shore Long Island Jewish Medical Center, The Hofstra North Shore-LIJ School of MedicineLake SuccessUSA
  2. 2.Pediatric RheumatologyChildren’s Hospital of University of IllinoisChicagoUSA
  3. 3.Department of Allergology, Rheumatology and Clinical Immunology, Children’s HospitalUniversity Medical Center LjubljanaLjubljanaSlovenia
  4. 4.Department of Pediatrics, Faculty of MedicineUniversity of LjubljanaLjubljanaSlovenia
  5. 5.Pediatric RheumatologySugar LandUSA

Personalised recommendations